Clinical Trial Update: Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of Telintra (TLK199) in patients with deletion 5q myelodysplastic syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Telintra

Snippet

Sponsor: Telik | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED